Unicet Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$29.5M
- Investors
-
11
Unicet General Information
Description
Developer of cell-based immunological agents intended for therapeutic use. The company offers engineered γδ T cells integrated with universal CAR constructs, supported by proprietary modulation of butyrophilin pathways and scalable allogeneic manufacturing processes, serving oncology and immunology markets to access off-the-shelf cellular therapies with enhanced targeting precision, reduced production time, and broader applicability across solid and hematologic malignancies.
Contact Information
Website
www.unicetbio.comCorporate Office
- 3rd Floor, Building 7, Number 20, Life Science Park Road
- Changping District
- Beijing, 102206
- China
Corporate Office
- 3rd Floor, Building 7, Number 20, Life Science Park Road
- Changping District
- Beijing, 102206
- China
Unicet Timeline
Unicet Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A1) | 12-Jun-2026 | $29.5M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series A1) | 21-Jul-2025 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 07-Feb-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 22-Nov-2021 | Completed | Generating Revenue | |||
| 2. Seed Round | 20-May-2019 | $1.48M | Completed | Startup | ||
| 1. Seed Round | 01-Mar-2019 | $1.48M | $1.48M | Completed | Startup |
Unicet Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Unicet Patents
Unicet Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| FR-2560212-B1 | Monoclonal antibodies against interferon a2 and hybridomas producing such antibodies | Inactive | 24-Feb-1984 | ||
| FR-2560212-A1 | Monoclonal antibodies against interferon a2 and hybridomes producing such antibodies | Active | 24-Feb-1984 |
Unicet Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Beijing State-owned Capital Operation and Management | Government | Minority | ||
| Beijing Zhongguancun Capital Fund Management | Growth/Expansion | Minority | ||
| Shenzhen Capital Group | Venture Capital | Minority | ||
| Flyfot Ventures | Venture Capital | Minority | ||
| Nanyang Zhongguancun Collaborative Entrepreneurship Investment Fund Management | Venture Capital | Minority |
Unicet FAQs
-
When was Unicet founded?
Unicet was founded in 2018.
-
Where is Unicet headquartered?
Unicet is headquartered in Beijing, China.
-
What industry is Unicet in?
Unicet’s primary industry is Biotechnology.
-
Is Unicet a private or public company?
Unicet is a Private company.
-
What is Unicet’s current revenue?
The current revenue for Unicet is .
-
How much funding has Unicet raised over time?
Unicet has raised $46.6M.
-
Who are Unicet’s investors?
Beijing State-owned Capital Operation and Management, Beijing Zhongguancun Capital Fund Management, Shenzhen Capital Group, Flyfot Ventures, and Nanyang Zhongguancun Collaborative Entrepreneurship Investment Fund Management are 5 of 11 investors who have invested in Unicet.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
